XYLOCAINE Drug Patent Profile

Which patents cover Xylocaine, and when can generic versions of Xylocaine launch?

Xylocaine is a drug marketed by Astrazeneca, Fresenius Kabi Usa, Epic Pharma Llc, and Dentsply Pharm. and is included in fourteen NDAs.

The generic ingredient in XYLOCAINE is epinephrine; lidocaine hydrochloride. There are twenty-one drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the epinephrine; lidocaine hydrochloride profile page.

Summary for XYLOCAINE

US Patents:	0
Applicants:	4
NDAs:	14

US Patents and Regulatory Information for XYLOCAINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Fresenius Kabi Usa	XYLOCAINE W/ EPINEPHRINE	epinephrine; lidocaine hydrochloride	INJECTABLE;INJECTION	006488-019	Nov 13, 1986	AP	RX	Yes	Yes
Astrazeneca	XYLOCAINE W/ EPINEPHRINE	epinephrine; lidocaine hydrochloride	INJECTABLE;INJECTION	010418-008	Approved Prior to Jan 1, 1982		DISCN	No	No
Fresenius Kabi Usa	XYLOCAINE W/ EPINEPHRINE	epinephrine; lidocaine hydrochloride	INJECTABLE;INJECTION	006488-004	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes
Fresenius Kabi Usa	XYLOCAINE W/ EPINEPHRINE	epinephrine; lidocaine hydrochloride	INJECTABLE;INJECTION	006488-012	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes
Astrazeneca	XYLOCAINE	lidocaine	AEROSOL;ORAL	014394-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Xylocaine Investment Analysis: Lidocaine Fundamentals, Patent Risk, Market Outlook, and Generic Competition

Last updated: July 31, 2026

Xylocaine is the branded form of lidocaine, a mature local anesthetic and antiarrhythmic. Its active-ingredient patents and most formulation patents expired long ago. The investment case therefore depends on brand recognition, regulatory approvals, manufacturing reliability, hospital contracts, distribution, and product-line economics rather than exclusivity.

Xylocaine has low strategic value as a standalone patent asset but can retain commercial value as a dependable injectable, topical, dental, and procedural anesthetic franchise. Generic lidocaine creates persistent price pressure, while differentiated presentations such as sprays, gels, cartridges, and ready-to-use products can preserve higher margins.

What is Xylocaine and how does the drug generate revenue?

Xylocaine contains lidocaine, also known as lignocaine in some markets. Lidocaine blocks sodium channels and is used for local or regional anesthesia. Certain injectable formulations are also approved for ventricular arrhythmias.

Attribute	Xylocaine
Active ingredient	Lidocaine or lidocaine hydrochloride
Drug class	Amide local anesthetic; selected injectable products are antiarrhythmics
Common dosage forms	Injectable solution, topical solution, jelly, ointment, cream, spray, dental cartridge
Main customers	Hospitals, ambulatory surgery centers, dental practices, emergency departments, clinics, pharmacies
Regulatory category	Prescription and, for some lidocaine products and strengths, nonprescription depending on jurisdiction
Primary competitors	Generic lidocaine products; bupivacaine, ropivacaine, mepivacaine, prilocaine, benzocaine
Exclusivity driver	Brand, supply, formulation, registration, and contracting rather than active-ingredient patents

The revenue model is fragmented. A company may sell Xylocaine through hospital tenders, institutional distributors, dental channels, retail pharmacies, or specialty medical distributors. Sales depend on units, concentration, dosage form, geography, and contract pricing.

The brand does not represent a single global product. Xylocaine formulations and rights vary by country. A product marketed as Xylocaine in one jurisdiction may be supplied by a different licensee or manufacturer in another.

Who owns and markets Xylocaine?

Xylocaine has historically been associated with AstraZeneca, which developed and commercialized the brand. Ownership, manufacturing, and distribution arrangements differ by country and product.

In the United States, many lidocaine products are sold as generics by companies such as Fresenius Kabi, Pfizer-associated businesses, Hikma, Sagent, Akorn-related entities, and other approved manufacturers, depending on product and market availability. The presence of a generic lidocaine product does not establish that the product is marketed under the Xylocaine trademark.

The commercial diligence question is therefore product-specific:

1. Who owns the Xylocaine trademark in the target country?
2. Who holds the local marketing authorization?
3. Who manufactures the product?
4. Is supply internal, contract-manufactured, or licensed?
5. Does the product have an approved generic equivalent?
6. Is the product included in institutional tenders or preferred formulary contracts?

A global valuation based only on the Xylocaine name would overstate the asset unless it identifies the legal owner, approved presentations, and net sales by jurisdiction.

What patents protect Xylocaine and lidocaine?

The original composition-of-matter protection for lidocaine expired decades ago. Xylocaine therefore does not have meaningful remaining exclusivity based on the active ingredient.

Patent category	Current investment relevance
Lidocaine composition patent	Expired
Basic local-anesthetic use patents	Expired
Standard injectable formulations	Generally expired
Conventional topical formulations	Generally expired
Delivery-system patents	Potentially relevant only for specific modern products
Manufacturing-process patents	May affect cost or supply but rarely block ordinary generic entry
Trademark rights	Potentially valuable for brand positioning and market access
Regulatory registrations	Relevant to continued sale but do not create broad market exclusivity

Formulation patents can matter for a specific product if they cover a proprietary concentration, excipient system, metered spray, patch, device, or combination. They do not restore exclusivity to ordinary lidocaine injection or conventional lidocaine cream.

A patent search should distinguish:

• Xylocaine-branded products;
• lidocaine active-ingredient products;
• lidocaine-prilocaine combinations;
• transdermal lidocaine systems;
• liposomal or extended-release local anesthetics;
• proprietary applicators and delivery devices.

Those categories have different patent profiles. Xylocaine should not be analyzed as though patents covering a newer lidocaine delivery system protect the entire lidocaine market.

When does Xylocaine lose exclusivity?

Xylocaine’s core pharmaceutical exclusivity has already expired. Generic lidocaine entry is established in major markets, including the United States and Europe.

The relevant commercial timetable is not a future patent cliff. It is the continuing erosion of brand share as hospitals, pharmacies, and clinicians substitute generic products. The key variables are tender cycles, shortages, manufacturer exits, and product-specific approvals.

United States exclusivity and Orange Book status

The FDA Orange Book identifies approved drug products and certain patent and exclusivity information. Legacy Xylocaine products may appear under historical or current application records, while many lidocaine products are approved under separate abbreviated or full applications. Product status must be checked by dosage form and application number rather than by brand name alone.[1]

For investment purposes:

• No broad, enforceable U.S. patent barrier is expected to prevent generic lidocaine injection or ordinary topical lidocaine competition.
• Paragraph IV litigation is not the central risk to the established Xylocaine franchise.
• ANDA competition is already the market structure for standard lidocaine products.
• A new generic may still face manufacturing, bioequivalence, facility, labeling, or supply requirements even when patent barriers are absent.

European and other geographic markets

European market access depends on national marketing authorizations, mutual-recognition or decentralized procedures, local reimbursement, and hospital procurement. Patent expiry is not the primary barrier for conventional lidocaine products.

In emerging markets, brand loyalty and distributor relationships can support Xylocaine pricing. Those advantages are weaker where public procurement uses international nonproprietary names and awards contracts primarily on price.

Are there Paragraph IV challenges to Xylocaine?

Paragraph IV litigation is generally associated with a generic applicant asserting that a listed patent is invalid, unenforceable, or not infringed. Because lidocaine and conventional Xylocaine formulations are mature products, the major competitive threat is ordinary generic substitution rather than a new wave of Paragraph IV challenges.

A Paragraph IV filing could become relevant if a rights holder listed a patent covering:

• a new delivery mechanism;
• a specific topical formulation;
• a combination product;
• a device-integrated presentation;
• a new indication;
• a long-acting or extended-release formulation.

Such a challenge would affect the patented presentation, not necessarily standard Xylocaine products. Investors should avoid treating any litigation involving a lidocaine-based product as litigation against the entire Xylocaine franchise.

What is the FDA regulatory status of Xylocaine?

Lidocaine is an established FDA-approved active ingredient. Approved uses depend on the specific formulation, strength, route, and labeling.

Common regulatory categories include:

• local or regional anesthesia;
• topical anesthesia for mucous membranes or skin;
• dental anesthesia;
• treatment of certain ventricular arrhythmias for injectable products;
• limited over-the-counter topical uses at specified concentrations and labeling conditions.

Safety and regulatory risks include systemic toxicity, seizures, cardiovascular effects, methemoglobinemia in certain contexts, dosing errors, accidental intravascular administration, and misuse on damaged or highly permeable skin. Product labels differ materially, so an investment assessment must not generalize safety data from one presentation to another.[2][3]

Regulatory value is higher for products with:

• established hospital protocols;
• broad institutional formularies;
• validated sterile manufacturing;
• reliable packaging;
• consistent concentration and presentation;
• approved indications that support procedural use.

What formulations are protected by Xylocaine?

Standard Xylocaine formulations are commercially mature. Differentiation is more likely to come from delivery and convenience than from active-ingredient protection.

Formulation	Competitive profile
Injectable lidocaine	Highly commoditized; hospital supply and price are decisive
Dental cartridge	More dependent on dental distribution, packaging, and procurement
Topical ointment or cream	Generic competition and retail shelf positioning
Oral or mucosal jelly	Brand familiarity may support demand, but substitution is available
Metered spray	Device and dosing convenience can support differentiation
Combination topical products	May have separate formulation or regulatory considerations
Patch or extended-release system	Separate product category with potentially stronger IP

A branded formulation can maintain a price premium when the buyer values consistency, dosing convenience, packaging, or reduced preparation time. That premium is vulnerable when a generic equivalent is therapeutically interchangeable and hospitals operate under fixed budgets.

How strong is the Xylocaine patent estate?

The patent estate is weak as a conventional pharmaceutical exclusivity asset and moderate as a brand and regulatory asset.

Dimension	Assessment
Composition-of-matter protection	Very weak; expired
Standard formulation protection	Weak
Delivery-system protection	Product-specific; potentially moderate
Trademark value	Moderate in established clinical markets
Manufacturing know-how	Potentially valuable for sterile supply and quality control
Regulatory file value	Useful, but not equivalent to exclusivity
Switching costs	Low for standard lidocaine products
Generic substitution risk	High
Biosimilar risk	Not applicable
Litigation leverage	Low for conventional products

The main defensible assets are operational. A supplier that consistently avoids shortages, meets sterile-manufacturing standards, and wins hospital contracts may outperform a lower-cost competitor despite lacking patent protection.

What generic entry risks exist for Xylocaine?

Generic entry is already established, so the relevant risk is continuing commoditization.

Price erosion

Standard lidocaine injection is exposed to tender pricing and multi-source generic competition. Net prices can fall when additional manufacturers enter, although shortages or manufacturing disruptions can temporarily reverse price pressure.

Formulary substitution

Hospitals and ambulatory centers often substitute approved generic products when the active ingredient, concentration, route, and packaging satisfy institutional requirements. Brand prescribing has limited defensive value in these settings.

Supply disruption

Lidocaine is inexpensive but operationally sensitive. Sterile injectables require compliant facilities, validated processes, and reliable component supply. Manufacturer exits can create shortages and give remaining suppliers temporary pricing power.

Regulatory and quality risk

Recalls, particulate contamination, concentration errors, container defects, and manufacturing observations can damage a supplier’s position. For an established injectable product, quality performance may matter more than brand advertising.

Does Xylocaine face biosimilar competition?

No. Xylocaine is a small-molecule lidocaine product, not a biologic. Biosimilar pathways do not apply.

Its competitive risk comes from:

• generic lidocaine;
• alternative local anesthetics;
• combination products;
• newer delivery systems;
• nonpharmacologic or procedural substitutes in limited settings.

Bupivacaine and ropivacaine can compete in procedures requiring longer duration. Benzocaine and prilocaine compete in selected topical uses. The products are not clinically interchangeable in every application, but procurement decisions can shift between agents based on duration, toxicity profile, cost, and clinician preference.

What patent litigation affects Xylocaine?

The principal litigation exposure is likely to arise from newer lidocaine-related products rather than the original Xylocaine franchise.

Potential disputes may involve:

• patents on transdermal delivery systems;
• extended-release local anesthetics;
• topical combinations;
• proprietary applicators;
• method-of-use claims;
• manufacturing processes;
• trademark infringement and parallel-import issues.

For conventional Xylocaine injection, litigation is less likely to create a durable barrier because the active ingredient and basic formulations are mature. A litigation review should search the branded product, the relevant NDA or marketing authorization, the manufacturer, and each approved formulation separately.

Are there licensing deals involving Xylocaine?

Xylocaine’s commercial history includes regional licensing, distribution, and manufacturing arrangements associated with the brand and its formulations. These agreements can affect the economic value of the asset even when patents have expired.

Key contract terms include:

• territory;
• product scope;
• trademark rights;
• manufacturing responsibility;
• minimum purchase obligations;
• supply commitments;
• price-adjustment provisions;
• quality and pharmacovigilance duties;
• change-of-control rights;
• termination triggers.

A licensee may have a profitable local business without owning the underlying trademark globally. Conversely, a trademark owner may receive limited economics if a distributor controls access to hospitals and pharmacies.

What is the investment scenario for Xylocaine?

Base case: stable mature-product cash flow

The base case is a low-growth, defensively positioned product with continued demand in anesthesia, dentistry, emergency care, and outpatient procedures. Revenue is supported by recurring clinical use, but pricing remains under pressure.

This scenario is most attractive for a manufacturer with:

• low production costs;
• high facility utilization;
• reliable sterile capacity;
• favorable hospital contracts;
• a broad product portfolio;
• efficient distribution.

Upside case: supply-constrained pricing and portfolio expansion

Upside can arise from competitor shortages, manufacturing exits, or acquisition of complementary local-anesthetic products. A supplier with available capacity may gain volume and temporary pricing power.

The brand can also benefit from line extensions, including:

• new concentrations;
• improved packaging;
• metered delivery;
• dental presentations;
• combination products;
• institutional ready-to-use formats.

These opportunities are commercial rather than patent-driven.

Downside case: accelerated commoditization

Downside arises from additional generic entrants, hospital tender losses, reimbursement reductions, manufacturing failures, or substitution by competing anesthetics. A branded product without meaningful formulation differentiation can lose share rapidly when buyers prioritize price.

Strategic acquisition case

Xylocaine may have value as part of a broader hospital or procedural-care portfolio. The asset is more attractive when it improves manufacturing utilization, fills distributor relationships, or increases the scale of a local-anesthetic franchise.

A standalone acquisition at a premium valuation would require evidence of:

• durable brand price premium;
• protected formulation rights;
• constrained competition;
• strong local market share;
• stable supply economics;
• favorable licensing terms.

How does Xylocaine compare with newer local anesthetics?

Product	Main advantage	Main commercial risk
Xylocaine/lidocaine	Rapid onset, broad familiarity, low cost	Generic substitution and limited duration
Bupivacaine	Longer duration	Toxicity concerns and generic competition
Ropivacaine	Duration and safety positioning in selected uses	Higher cost and established alternatives
Benzocaine	Topical convenience	Narrower use and safety restrictions
Prilocaine combinations	Topical efficacy in selected settings	Combination-product competition
Extended-release lidocaine systems	Potentially longer duration or convenience	Higher development cost and patent exposure

Lidocaine remains important because clinicians know its dosing and onset characteristics. Its commercial weakness is that those same characteristics are available from many generic suppliers.

What revenue exposure does Xylocaine create for investors?

Xylocaine-specific revenue is difficult to isolate because the brand may be bundled with other mature products and reported within a larger anesthesia or hospital portfolio. Public-company disclosures often report therapeutic-area or segment revenue rather than individual legacy brands.

Revenue exposure should be modeled using:

• units by formulation;
• net price by channel;
• generic substitution rate;
• tender renewal dates;
• shortage-driven volume assumptions;
• manufacturing cost per unit;
• regulatory remediation costs;
• royalty or distribution payments.

A simple mature-brand model should use modest volume growth, declining or flat net price, and sensitivity to supply interruptions. The model should not assume patent-driven price protection.

Key Takeaways

• Xylocaine is a lidocaine brand with broad clinical use and mature demand.
• Core lidocaine patents have expired; the asset has little conventional patent exclusivity.
• Generic competition is established and is the principal commercial risk.
• Biosimilar competition does not apply because lidocaine is a small molecule.
• Standard injections and conventional topical products are highly commoditized.
• Formulation, device, packaging, and delivery-system rights can create product-specific differentiation.
• Supply reliability and sterile-manufacturing quality may matter more than trademark strength.
• Xylocaine is more attractive as part of a scaled hospital or procedural-care portfolio than as a standalone patent asset.
• Valuation should focus on net sales, tender access, manufacturing economics, local trademark rights, and competitive supply.

Frequently Asked Questions

Is Xylocaine still patent protected?

The active ingredient and conventional lidocaine formulations are not protected by current composition patents. Specific delivery systems or newer formulations may have separate patents.

Is Xylocaine the same as lidocaine?

Xylocaine is a brand name for products containing lidocaine. The exact formulation, concentration, route, and approved indication determine whether a generic lidocaine product is therapeutically substitutable.

Can generic manufacturers launch lidocaine without a Paragraph IV lawsuit?

For mature lidocaine products with no blocking patents, generic manufacturers may enter through the applicable FDA approval pathway without relying on a successful Paragraph IV challenge. Product-specific patent listings must still be reviewed.

Does Xylocaine have a durable hospital pricing premium?

Usually not for standard injectable products. Hospital pricing is driven by tenders, formulary policy, supply reliability, and generic availability. A premium is more defensible for differentiated packaging, devices, or specialized presentations.

What is the strongest investment angle in the Xylocaine franchise?

The strongest angle is operational scale: reliable sterile manufacturing, hospital distribution, shortage capture, and portfolio bundling. The weakest angle is a thesis based on future patent exclusivity for standard lidocaine products.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.
2. U.S. Food and Drug Administration. (2024). Lidocaine hydrochloride injection prescribing information. DailyMed and FDA labeling database.
3. National Library of Medicine. (2024). Lidocaine drug label information. DailyMed.
4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
5. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA, Center for Drug Evaluation and Research.